Specific Hyperimmune Globulin for Cytomegalovirus Pneumonitis

Blacklock, Hilary; Griffiths, Paul; Stirk, P. R.; Prentice, H. G.

doi:10.1016/s0140-6736(85)90252-1

Cited by 50 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Per the manufacturer's recommendations, prophylaxis consisted in 7 intravenous (IV) doses of 100 UI/kg every 2–3 weeks for 3 months. Treatment prescription guidelines were 400 UI/kg IV at initiation and at D4 and D8, followed by 200 UI/kg at D12 and D16 27 …”

Section: Methodsmentioning

confidence: 99%

“…Treatment prescription guidelines were 400 UI/kg IV at initiation and at D4 and D8, followed by 200 UI/kg at D12 and D16. 27 Data on the initial prescription, including injection dose and frequency, and on the total number of injections administered were collected for each patient. CMVIG was considered to have been prescribed as combination therapy if one of the following treatments was also prescribed: ganciclovir, valganciclovir, foscavir, or mTor inhibitors.…”

Section: Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience

Roy

Parquin

Messika

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

Rational Pending the authorization of new anti‐CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official authorization by the national Health authority and is restricted to second line rescue therapy for CMV infection/disease. The aim of this multicenter retrospective study is to describe the indications and clinical situations that justified its use in France. Methods A multicenter retrospective study included 22 lung transplant patients over a 3‐year period. Data on clinical indication, tolerance and efficacy were collected. Results The main indication for CMVIG initiation, which was documented in 17 of them (82%) was complex clinical situations resulting from side effects to antiviral drug. CMVIG indication was documented as treatment for 15 patients (68%) and as a secondary prophylaxis for 7 patients (32%). Only one side effect (pruritus during infusion with no anaphylactic symptoms) attributable to CMVIG was reported. After CMVIG initiation, no recurrence of infection or disease was observed during a median follow‐up of 174 (12–682) days after treatment initiation for respectively 68% and 66% of the patients. Conclusion This study describes an unusual indication of CMVIG use as a last resort treatment in complex situations, based on clinical needs. CMVIG could be useful to change the course of CMV infection with minimal adverse effects or comorbidity.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%

Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience

Roy

Parquin

Messika

et al. 2021

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Because the immune system is immature in most fetuses, administration of CMV hyperimmunoglobulin can provide passive antibodies to the CMV‐infected fetus. This notion is based on the results of immunotherapy for immunodeficient, CMV‐infected patients 6–8 …”

Section: Discussionmentioning

confidence: 99%

Intrauterine therapy with cytomegalovirus hyperimmunoglobulin for a fetus congenitally infected with cytomegalovirus

Sato

Hirano

Miura

et al. 2007

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Reported herein is a case of hydrops fetalis in which the cord blood expressed cytomegalovirus (CMV) antigen. Fetal ascites was removed from an infected fetus with hydrops in utero and 2.5 g CMV hyperimmunoglobulin was administered into the fetal abdominal cavity at 28 weeks gestation. After immunoglobulin administration, fetal ascites vanished, preload index of the inferior vena cava decreased and platelet count of the infant increased. However, despite intrauterine therapy and intensive neonatal care, the infant died soon after birth. The expression of CMV antigen in the nucleus of polymorphonuclear leukocytes in fetal cord blood indicated that the fetal hydrops was caused by CMV infection. When symptomatic CMV infection of a fetus is suspected from serological and ultrasound findings, further examinations should be performed for the diagnosis. Intrauterine immunoglobulin therapy could be one of the therapeutic options for the affected fetus.

show abstract

“…More over, it should be noted that at least some of the so-called anti-CMV hyperimmunoglobulins are only slightly en riched in these antibodies when compared to the standard preparations [39]. Blacklock et al [40] have recently reported good results with Cytotect®. Their patients received within 16 days a total of 1.6 g of this preparation per kilogram body weight.…”

Section: Use Of Ivig In Immune-compromised Patients With Generalized mentioning

confidence: 99%

Intravenous Immunoglobulins: Pharmacological Aspects and Therapeutic Use

Hässig¹

1986

Vox Sanguinis

View full text Add to dashboard Cite

The requirements for a present-day IVIG preparation are outlined. These are mainly: fully preserved activities of the recognition and effector functions of the IgG molecule, a normal subclass distribution, and a normal half-life after infusion. The therapeutic uses of IVIG preparations are discussed as follows: (1) Antibody substitution in cases of generalized or partial antibody deficiency in immune-compromised patients. These include the following diseases: hypogammaglobulinemia (congenital and aquired, including the neonates); drug-induced and viral immunosuppression. (2) Antibody substitution in cases of selective antibody deficiency in otherwise immune-competent patients. These include acute cases of consumptive antibody deficiencies of the Jarisch-Herxheimer reaction type; in particular, chronic inflammations which apparently involve ineffective immune responses in which the organism is unable to build up sufficient amounts of antibodies with the required partial specificity, which is indispensable for overcoming the disease. (3) Modulation of the immune system by Ig-Ig interactions (mainly idiotype-anti-idiotype interactions) and Ig-Fc-receptor interactions, as it is known from the RES blockade during IVIG treatment of idiopathic thrombocytopenic purpura.

show abstract

Specific Hyperimmune Globulin for Cytomegalovirus Pneumonitis

Cited by 50 publications

References 0 publications

Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience

Use of anti‐CMV immunoglobulins in lung transplant recipients: The French experience

Intrauterine therapy with cytomegalovirus hyperimmunoglobulin for a fetus congenitally infected with cytomegalovirus

Intravenous Immunoglobulins: Pharmacological Aspects and Therapeutic Use

Contact Info

Product

Resources

About